The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment

Critical Care Medicine

Volumn 40, Issue 7, 2012, Pages 2016-2021

  Labelle, Andrew ^a   Juang, Paul ^b   Reichley, Richard ^c   Micek, Scott ^d   Hoffmann, Justin ^b   Hoban, Alex ^a   Hampton, Nicholas ^c   Kollef, Marin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c Hospital Informatics Group   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

Author keywords

Antibiotics; Gram negative; Outcome; Resistance; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BLOODSTREAM INFECTION; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; PRIORITY JOURNAL; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; COHORT STUDIES; COMORBIDITY; CROSS INFECTION; ERYTHROCYTE TRANSFUSION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MISSOURI; MULTIVARIATE ANALYSIS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; YOUNG ADULT;

EID: 84862760687     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318250aa72     Document Type: Article

References (31)

1. Kollef MH: Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13
2. Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003; 31:2291-2301
3. Dupont H, Mentec H, Sollet JP, et al: Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362 (Pubitemid 32249978)
4. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742-2751 (Pubitemid 38010630)
5. Harbarth S, Garbino J, Pugin J, et al: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535 (Pubitemid 37352798)
6. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155 (Pubitemid 30485502)
7. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474 (Pubitemid 29083057)
8. Micek ST, Lloyd AE, Ritchie DJ, et al: Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311 (Pubitemid 40463352)
9. Shorr AF, Micek ST, Welch EC, et al: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011; 39:46-51
10. Ferrer R, Artigas A, Suarez D, et al: Edusepsis Study Group: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-866
11. Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century- A clinical super-challenge. N Engl J Med 2009; 360:439-443
12. Boucher HW, Talbot GH, Bradley JS, et al: Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12
13. Dellinger RP, Levy MM, Carlet JM, et al: International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
14. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829 (Pubitemid 15250137)
15. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310 (Pubitemid 32641789)
16. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281
17. Micek ST, Roubinian N, Heuring T, et al: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707-2713 (Pubitemid 44610934)
18. Thiel SW, Asghar MF, Micek ST, et al: Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med 2009; 37:819-824
19. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania, 2002
20. Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. Clinical Laboratory Standards Institute, Wayne, Pennsylvania, 2007
21. Zahar JR, Timsit JF, Garrouste-Orgeas M, et al: Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886-1895
22. Puskarich MA, Trzeciak S, Shapiro NI, et al: Emergency Medicine Shock Research Network (EMSHOCKNET): Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39:2066-2071
23. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596 (Pubitemid 43810035)
24. Joo EJ, Kang CI, Ha YE, et al: Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: A stratified analysis according to sites of infection. Infection 2011; 39: 309-318
25. Le Berre R, Nguyen S, Nowak E, et al: Pyopneumagen Group: Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med 2011; 39:2113-2120
26. Hauser AR, Cobb E, Bodi M, et al: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-528 (Pubitemid 34214611)
27. Deleo FR, Otto M, Kreiswirth BN, et al: Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557-1568
28. Cohen J: A role for the micro-organism in the outcome from infection? A principle challenged. Crit Care Med 2011; 39:2001-2002
29. Holmes NE, Turnidge JD, Munckhof WJ, et al: Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-347
30. Rodriguez A, Lisboa T, Blot S, et al: Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators: Mortality in ICU patients with bacterial community-acquired pneumonia: When antibiotics are not enough. Intensive Care Med 2009; 35:430-438
31. U.S. Food and Drug Administration: Xigris [drotrecogin alfa (activated)]: Market Withdrawal-Failure to Show Survival Benefit. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformat ion/ SafetyAlertsforHumanMedicalProducts/ucm277143.htm. Accessed October 28, 2011